Back to top
more

QuidelOrtho (QDEL)

(Delayed Data from NSDQ)

$39.69 USD

39.69
913,570

-1.13 (-2.77%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $39.67 -0.02 (-0.05%) 7:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing

by Zacks Equity Research

QuidelOrtho's (QDEL) addition of the Fentanyl Test is likely to deliver rapid drugs-of-abuse detection amidst the escalating opioid crisis.

QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing

by Zacks Equity Research

QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.

QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.

QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall

by Zacks Equity Research

Despite solid performances by the Labs segment and China and Other regions, QuidelOrtho (QDEL) misses earnings and revenue estimates by 41.8% and 6.9%, respectively.

QuidelOrtho (QDEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for QuidelOrtho (QDEL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

QuidelOrtho (QDEL) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of -42.08% and 6.97%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Insights Into QuidelOrtho (QDEL) Q4: Wall Street Projections for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for QuidelOrtho (QDEL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Earnings Due on Feb 13: ECL, DVA & QDEL

by Indrajit Bandyopadhyay

Medical Device companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how ECL, DVA and QDEL fare this time.

QuidelOrtho's (QDEL) Latest FDA Nod to Boost Diagnostic Testing

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of the FDA's latest approval is likely to improve clinical care, provide cost savings and deliver sample-to-result molecular testing across all laboratory settings.

Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now

by Zacks Equity Research

QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.

QuidelOrtho (QDEL) Q3 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Despite solid performances by the Labs and TM segments and China and Other regions, QuidelOrtho (QDEL) reports soft overall top-line results in third-quarter 2023.

QuidelOrtho (QDEL) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for QuidelOrtho (QDEL) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Indrajit Bandyopadhyay headshot

Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More

by Indrajit Bandyopadhyay

Medical Device companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, QDEL, GKOS and NARI are placed ahead of their earnings release.

Haemonetics (HAE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-respiratory product sales.

QuidelOrtho's (QDEL) Rapid Antigen Test Gets CLIA Waiver

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of the FDA's CLIA waiver is expected to widen access to the rapid antigen test in any point-of-care setting equipped with Sofia 2 instruments.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.

Are Investors Undervaluing Koninklijke Philips (PHG) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Down -14% in 4 Weeks, Here's Why You Should You Buy the Dip in QuidelOrtho (QDEL)

by Zacks Equity Research

QuidelOrtho (QDEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

QuidelOrtho (QDEL) Q2 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Despite solid performances by the Labs segment and Other region, QuidelOrtho (QDEL) reports soft overall top-line results in second-quarter 2023.

QuidelOrtho (QDEL) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for QuidelOrtho (QDEL) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

QuidelOrtho (QDEL) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 4% and 7.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Believe QuidelOrtho (QDEL) Could Rally 29.87%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 29.9% upside potential for QuidelOrtho (QDEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Sheraz Mian headshot

Top Research Reports for Microsoft, Salesforce & United Parcel Service

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Salesforce, Inc. (CRM) and United Parcel Service, Inc. (UPS).